Search
BIO-Europe 2025: Herantis Pharma is developing HER-096 for Parkinson's, a blood-brain-barrier penetrant small peptide molecule that is designed to mimic the activity of CDNF
CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year. Coverage brought to you by:
Nov 3
BIO-Europe 2025: Valneva's partner Pfizer has been running a key trial of a Lyme disease vaccine that has covered the last three seasons - it will read out in the first part of next year
Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine license. Coverage brought to you by:
Nov 3
Roche will pay Manifold Bio $55M up front, and up to $2B in milestones, to collaborate on multiple next-generation brain shuttles for neurological diseases
Manifold Co-Founders Gleb Kuznetsov and Pierce Ogden explain how Manifold is working on next generation shuttles, which means going beyond transferrin. They discuss the deal, and also Manifold's broader platform of high-throughput, in-vivo discovery work.
Nov 3
BIO-Europe 2025: ReNewVax CEO Neil Murray believes the antigens the company has found will enable it to develop a pneumococcal vaccine that targets all ca.100 existing variants
He describes the unmet need for a better vaccine than those already on the market, and says he is looking for a lead investor for a series A at BIO-Europe. Coverage brought to you by:
Nov 3
BIO-Europe 2025: Abivax CEO Marc de Garidel discusses physician and payor feedback after obefazimod's phase 3 UC induction readouts, and next steps regarding maintenance and Crohn's
He describes the mechanism of the therapy, as well the data and commercial landscape for UC. Plus, how he thinks about combos and business development. Coverage brought to you by:
Nov 3
BIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today
CEO Natalia Misciattelli describes the lead programs for Stargardt Disease and Usher 1B Syndrome, and how AAVantgarde is able to solve the problem of delivering genes that are naturally too large for single AAV vectors. Coverage brought to you by:
Nov 3
Mathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more.
He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer.
Oct 31
Sonoma Biotherapeutics announced early clinical data today in a late-breaker at #ACR25 for its CAR-Treg to treat rheumatoid arthritis. Co-Founders Jeff Bluestone and Fred Ramsdell walk us through it.
They explain why they believe a Treg based cell therapy is the right approach for autoimmune conditions, and describe the construct of this particular product. After discussing the data, they also comment on what they believe the big picture is for these types of Treg based treatments going forward.
Oct 29
Zag Bio launched today with $80M, and aims to tackle autoimmune disease by using antibodies to reprogram how Tregs and Teffs are created in the thymus. The lead indication will be Type 1 diabetes.
CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D program is scheduled to be in the clinic by late 2026.
Oct 28
Hemab Therapeutics, a company specializing in developing treatments for bleeding disorders, announced a $157 million series C raise today. CEO Benny Sorensen describes the work and unmet need.
The company's lead program, a bi-specific called Sutacimig, has already reported phase 2 data for Glanzmann Thrombasthenia, and will start a pivotal in 2026. Hemab also has a monovalent antibody (HMB-022) in the clinic for the world's most common bleeding disorder, Von Willebrand Disease, and will be announcing an additional candidate next year.
Oct 27
Weave Bio, which raised a $20M series A this month, is aiming to use software and LLMs to automate and streamline regulatory submissions for drug development
Co-Founder & CEO Brandon Rice says that in one project it worked on with a pharma, Weave's technology took only 3 hours to draft regulatory documents what would have taken humans to 100 hours.
Oct 23
Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1
He walks us through exon 44 and 45 programs, which will both likely have clinical readouts in 2026. Meanwhile, a $350M cash position gives Entrada the ability to think beyond neuromuscular conditions in the future as well.
Oct 22
Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)
He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.
Oct 22
Flagship Pioneering announced its newest company to emerge out of stealth mode today: Expedition Medicines. It is leveraging generative design for small molecule covalent chemistry
Co-Founder and CEO Molly Gibson explains the science behind the new company and the technology and equipment it uses for the work. Expedition has been funded with $50 million, and is also announcing a multi-target deal with Pfizer for prostate cancer.
Oct 22
Biotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the science behind the company's new focus in autoimmune that has him excited about the opportunity
He describes CUE-401, which combines a TGF-beta breathing-mask moiety with an interleukin (IL-2) mutein, and CUE-501, a Boehringer Ingelheim partnered program which is designed to deplete B-cells by painting them and engaging with virus-specific memory T-cells.
Oct 21
PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose
He describes the science behind PepGen's "Enhanced Delivery Oligonucleotide (EDO)" platform, and explains how he believes it gives the company a differentiated advantage in this condition by focusing on the pathogenic repeat that causes DM1 and restoring normal function.
Oct 15
Benchtalk 2025: Generate:Biomedicines' VP of Informatics Stephen Kottmann describes the investments in technology that ensures only the highest quality data returns back into its models
He walks us through the design, build, test, learn model that is the foundation of Generate's approach to drug development. Coverage brought to you by
Oct 14
Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial readouts scheduled in DMD and DM1 over the next year
He describes the science behind FORCE, which combines an antigen-binding fragment, a linker and, a payload. The company's DMD program will have a key trial readout before the end of this year, and DM1 will follow in 2026. Both programs could be filed for AA in 2026 with positive data. Coverage brought to you by
Oct 14
Sunrise Group, which has designed a mandibular sensor for at-home diagnosis of sleep apnea, recently raised $29M to expand its digital sleep clinic that patients can access remotely
Co-Founder & CEO Laurent Martinot discusses the raise, and the need for more accessible sleep health care. Plus, previewing a clinical...
Oct 10
Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBD
CEO Ros Deegan discusses the deal and the path to getting there, and she highlights some of OMass' other programs the company is driving...
Oct 9
.png){kind=logo}
